50+ MedTech cos funded, 25+ exitsexternal
4.3x realized cash multipleexternal
25+ active portfolio investmentsexternal
25 years MedTech investing track recordexternal
Proprietary clinical team for deal insightsexternal
Biotech & AI portfolio breadth visibletwitter
Multiple Series A–D portfolio milestonestwitter
COVID19 biotech bet (Neutrolist)twitter
DNA data encoding & tissue engineering betstwitter
AI-powered cardio robotics bet (Laza Medical)website
Commercial-stage surgical robotics (Distalmotion)website
Dual fund families: CardioVentures + 415 Capitalwebsite
Dedicated clinical team — proprietary deal flowwebsite
VTE clot removal platform (Endovascular Eng.)website
pVAD cardiogenic shock device (Supira Medical)website
Bioresorbable vascular scaffold (R3 Vascular)website
Microvascular obstruction therapy (CorFlow)website
HFrEF transcatheter repair (Cardiac Success)website
Blood pressure optimization platform (Hilo)website
Transcatheter tricuspid valve (TRiCares)website
Deep brain stimulation TBI therapy (ReEmerge)website
Team: investing + biomedical engineering + medicinewebsite
Physicians + clinical specialists on teamwebsite
Entrepreneurship & commercialization expertise in-housewebsite
Life-saving innovation focus, patient-centric thesiswebsite
Market access + capital + expertise value-addwebsite
Clinical team finger on pulse daily practicewebsite
Investment team spans med device commercializationwebsite
2026 RAISE Select: top 101 firms globallylinkedin
Specialist focus: cardiovascular + neurovascular onlylinkedin
Targets 50% global population disease burdenlinkedin
Deep clinical expertise + specialized approachlinkedin
